Pear Therapeutics (PEARW) Competitors

Venus Acquisition (NASDAQ:VENAW) and Pear Therapeutics (NASDAQ:PEARW) are both professional, scientific, and technical services companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Does the MarketBeat Community believe in VENAW or PEARW?

Venus Acquisition and Pear Therapeutics both received 0 outperform votes by MarketBeat users.

Company	Underperform	Outperform
Venus Acquisition	N/A	N/A
Pear Therapeutics	N/A	N/A

Is VENAW or PEARW more profitable?

Company	Net Margins	Return on Equity	Return on Assets
Venus Acquisition	N/A	N/A	N/A
Pear Therapeutics	N/A	N/A	N/A

Does the media refer more to VENAW or PEARW?

In the previous week, Pear Therapeutics' average media sentiment score of 0.00 equaled Venus Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Venus Acquisition	Neutral
Pear Therapeutics	Neutral

Do analysts rate VENAW or PEARW?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Pear Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Which has preferable earnings & valuation, VENAW or PEARW?

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Acquisition	N/A	N/A	N/A	N/A	N/A
Pear Therapeutics	N/A	N/A	N/A	N/A	N/A

Summary

Venus Acquisition and Pear Therapeutics tied by winning 0 of the 0 factors compared between the two stocks.